[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100536952":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":25,"locations":31,"responsibleParty":94,"collaborators":96,"id":100,"slug":10,"hasResults":101,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":10,"eligibilityCriteria":105,"healthyVolunteers":101,"sex":106,"minAge":10,"maxAge":10,"enrollmentInfo":107,"targetDuration":110,"studyType":111,"phases":10,"briefSummary":112,"conditions":113,"keywords":10,"overallStatus":34,"whyStopped":10,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":124},{"fullName":5,"class":6},"Genetix Biotherapeutics Inc.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"All Participants",null,"Participants with β-thalassemia treated with beti-cel in the post-marketing setting will be followed in this registry study for up to 15 years after infusion with beti-cel to collect real-world longitudinal data.",[13],"Other: No Intervention",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"OTHER","No Intervention","This is non-interventional study.",[9],[21],{"name":22,"affiliation":23,"role":24},"Himal Lal Thakar, MD","bluebird bio, Inc.","STUDY_DIRECTOR",[26],{"name":27,"role":28,"phone":29,"phoneExt":10,"email":30},"bluebird bio","CONTACT","+1-833-999-6378","clinicaltrials@bluebirdbio.com",[32,45,54,64,74,84],{"facility":33,"status":34,"city":35,"state":36,"zip":37,"country":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":10},"UCSF Benioff Children's Hospitals","RECRUITING","Oakland","California","94609","United States",{"type":40,"coordinates":41},"Point",[42,43],-122.2708,37.80437,{"lat":43,"lon":42},{"facility":46,"status":34,"city":47,"state":36,"zip":48,"country":38,"cosmosGeoPoint":49,"geoPoint":53,"contacts":10},"Stanford University","Palo Alto","94043",{"type":40,"coordinates":50},[51,52],-122.14302,37.44188,{"lat":52,"lon":51},{"facility":55,"status":34,"city":56,"state":57,"zip":58,"country":38,"cosmosGeoPoint":59,"geoPoint":63,"contacts":10},"University of Minnesota","Minneapolis","Minnesota","55455",{"type":40,"coordinates":60},[61,62],-93.26384,44.97997,{"lat":62,"lon":61},{"facility":65,"status":34,"city":66,"state":67,"zip":68,"country":38,"cosmosGeoPoint":69,"geoPoint":73,"contacts":10},"Cohen Children's Medical Center","New Hyde Park","New York","11040",{"type":40,"coordinates":70},[71,72],-73.68791,40.7351,{"lat":72,"lon":71},{"facility":75,"status":34,"city":76,"state":77,"zip":78,"country":38,"cosmosGeoPoint":79,"geoPoint":83,"contacts":10},"Children's Hospital of Philadelphia","Philadelphia","Pennsylvania","19104",{"type":40,"coordinates":80},[81,82],-75.16362,39.95238,{"lat":82,"lon":81},{"facility":85,"status":34,"city":86,"state":87,"zip":88,"country":38,"cosmosGeoPoint":89,"geoPoint":93,"contacts":10},"Texas Children's Hospital","Houston","Texas","77030",{"type":40,"coordinates":90},[91,92],-95.36327,29.76328,{"lat":92,"lon":91},{"type":95,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[97],{"name":98,"class":99},"Center for International Blood and Marrow Transplant Research","NETWORK","100536952",false,"NCT06271512","A Study of Participants with Β-Thalassemia Treated with Betibeglogene Autotemcel","A Safety and Effectiveness Registry Study of Patients with Β-Thalassemia Treated with Betibeglogene Autotemcel (the Glostar Registry)","Inclusion Criteria:\n\n* Participant must be treated with beti-cel in the post marketing setting at a center in the US that participates in the Registry.\n* Participant must sign an informed consent and\u002For assent prior to enrollment as required under applicable laws and regulations.\n* Participant must have signed an informed consent and\u002For assent permitting data to be shared with Center for International Blood and Marrow Transplant Research (CIBMTR).\n* Participant must be followed by a hematologist based in the US.\n\nExclusion Criteria:\n\n\\- There are no exclusion criteria for Registry participation.","ALL",{"count":108,"type":109},150,"ESTIMATED","15 Years","OBSERVATIONAL","The main aim of this study is to collect real-world longitudinal data on participants with β-thalassemia treated with betibeglogene autotemcel (beti-cel) in the post marketing setting. To assess the long-term safety, including the risk of newly diagnosed malignancies, after treatment with beti-cel and evaluate the long-term effectiveness of treatment with beti-cel.",[114],"Beta-Thalassemia","2025-02-10",{"date":117,"type":118},"2025-02-11","ACTUAL",{"date":120,"type":118},"2024-01-23",{"date":122,"type":109},"2043-12",{"name":5,"class":6},6]